These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 16274992)

  • 1. Tethering identifies fragment that yields potent inhibitors of human caspase-1.
    Fahr BT; O'Brien T; Pham P; Waal ND; Baskaran S; Raimundo BC; Lam JW; Sopko MM; Purkey HE; Romanowski MJ
    Bioorg Med Chem Lett; 2006 Feb; 16(3):559-62. PubMed ID: 16274992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and evaluation of tricyclic pyrrolopyrimidinones as dipeptide mimetics: inhibition of interleukin-1beta-converting enzyme.
    Laufersweiler MC; Wang Y; Soper DL; Suchanek MK; Fancher AN; Lu W; Wang RL; Oppong KA; Ellis CD; Baize MW; O'Neil SV; Wos JA; Demuth TP
    Bioorg Med Chem Lett; 2005 Oct; 15(19):4322-6. PubMed ID: 16046129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, SAR, and X-ray structure of tricyclic compounds as potent FBPase inhibitors.
    Tsukada T; Takahashi M; Takemoto T; Kanno O; Yamane T; Kawamura S; Nishi T
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5909-12. PubMed ID: 19762234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and evaluation of thiazepines as interleukin-1beta converting enzyme (ICE) inhibitors.
    Ellis CD; Oppong KA; Laufersweiler MC; O'Neil SV; Soper DL; Wang Y; Wos JA; Fancher AN; Lu W; Suchanek MK; Wang RL; De B; Demuth TP
    Bioorg Med Chem Lett; 2006 Sep; 16(18):4728-32. PubMed ID: 16870441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel tricyclic inhibitors of IKK2: discovery and SAR leading to the identification of 2-methoxy-N-((6-(1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl)pyridin-2-yl)methyl)acetamide (BMS-066).
    Watterson SH; Langevine CM; Van Kirk K; Kempson J; Guo J; Spergel SH; Das J; Moquin RV; Dyckman AJ; Nirschl D; Gregor K; Pattoli MA; Yang X; McIntyre KW; Yang G; Galella MA; Booth-Lute H; Chen L; Yang Z; Wang-Iverson D; McKinnon M; Dodd JH; Barrish JC; Burke JR; Pitts WJ
    Bioorg Med Chem Lett; 2011 Dec; 21(23):7006-12. PubMed ID: 22018461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enantio- and diastereoselective total synthesis of EI-1941-1, -2, and -3, inhibitors of interleukin-1beta converting enzyme, and biological properties of their derivatives.
    Shoji M; Uno T; Kakeya H; Onose R; Shiina I; Osada H; Hayashi Y
    J Org Chem; 2005 Nov; 70(24):9905-15. PubMed ID: 16292821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The discovery of tricyclic pyridone JAK2 inhibitors. Part 1: hit to lead.
    Siu T; Kozina ES; Jung J; Rosenstein C; Mathur A; Altman MD; Chan G; Xu L; Bachman E; Mo JR; Bouthillette M; Rush T; Dinsmore CJ; Marshall CG; Young JR
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7421-5. PubMed ID: 21044843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reducing the peptidyl features of caspase-3 inhibitors: a structural analysis.
    Becker JW; Rotonda J; Soisson SM; Aspiotis R; Bayly C; Francoeur S; Gallant M; Garcia-Calvo M; Giroux A; Grimm E; Han Y; McKay D; Nicholson DW; Peterson E; Renaud J; Roy S; Thornberry N; Zamboni R
    J Med Chem; 2004 May; 47(10):2466-74. PubMed ID: 15115390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conformationally restricted hydantoin-based peptidomimetics as inhibitors of caspase-3 with basic groups allowed at the S3 enzyme subsite.
    Vázquez J; García-Jareño A; Mondragón L; Rubio-Martinez J; Pérez-Payá E; Albericio F
    ChemMedChem; 2008 Jun; 3(6):979-85. PubMed ID: 18393268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors.
    Jones P; Bottomley MJ; Carfí A; Cecchetti O; Ferrigno F; Lo Surdo P; Ontoria JM; Rowley M; Scarpelli R; Schultz-Fademrecht C; Steinkühler C
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3456-61. PubMed ID: 18440229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and evaluation of unsaturated caprolactams as interleukin-1beta converting enzyme (ICE) inhibitors.
    Wang Y; O'Neil SV; Wos JA; Oppong KA; Laufersweiler MC; Soper DL; Ellis CD; Baize MW; Fancher AN; Lu W; Suchanek MK; Wang RL; Schwecke WP; Cruze CA; Buchalova M; Belkin M; De B; Demuth TP
    Bioorg Med Chem; 2007 Feb; 15(3):1311-22. PubMed ID: 17127070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fragment-based discovery of nonpeptidic BACE-1 inhibitors using tethering.
    Yang W; Fucini RV; Fahr BT; Randal M; Lind KE; Lam MB; Lu W; Lu Y; Cary DR; Romanowski MJ; Colussi D; Pietrak B; Allison TJ; Munshi SK; Penny DM; Pham P; Sun J; Thomas AE; Wilkinson JM; Jacobs JW; McDowell RS; Ballinger MD
    Biochemistry; 2009 Jun; 48(21):4488-96. PubMed ID: 19284778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Mycobacterium tuberculosis protein tyrosine phosphatase A (MptpA) inhibitors based on natural products and a fragment-based approach.
    Manger M; Scheck M; Prinz H; von Kries JP; Langer T; Saxena K; Schwalbe H; Fürstner A; Rademann J; Waldmann H
    Chembiochem; 2005 Oct; 6(10):1749-53. PubMed ID: 16196020
    [No Abstract]   [Full Text] [Related]  

  • 14. Development of a novel tricyclic class of potent and selective FIXa inhibitors.
    Meng D; Andre P; Bateman TJ; Berger R; Chen YH; Desai K; Dewnani S; Ellsworth K; Feng D; Geissler WM; Guo L; Hruza A; Jian T; Li H; Metzger J; Parker DL; Reichert P; Sherer EC; Smith CJ; Sonatore LM; Tschirret-Guth R; Wu J; Xu J; Zhang T; Campeau LC; Orr R; Poirier M; McCabe-Dunn J; Araki K; Nishimura T; Sakurada I; Hirabayashi T; Wood HB
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5437-43. PubMed ID: 26318999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity relationship analysis of a novel necroptosis inhibitor, Necrostatin-5.
    Wang K; Li J; Degterev A; Hsu E; Yuan J; Yuan C
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1455-65. PubMed ID: 17270434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationship study of tricyclic necroptosis inhibitors.
    Jagtap PG; Degterev A; Choi S; Keys H; Yuan J; Cuny GD
    J Med Chem; 2007 Apr; 50(8):1886-95. PubMed ID: 17361994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards a model for the inhibition of choline kinase by a new type of inhibitor.
    Conejo-García A; Entrena A; Campos JM; Sánchez-Martín RM; Gallo MA; Espinosa A
    Eur J Med Chem; 2005 Mar; 40(3):315-9. PubMed ID: 15725501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The core structures of roseophilin and the prodigiosin alkaloids define a new class of protein tyrosine phosphatase inhibitors.
    Fürstner A; Reinecke K; Prinz H; Waldmann H
    Chembiochem; 2004 Nov; 5(11):1575-9. PubMed ID: 15515092
    [No Abstract]   [Full Text] [Related]  

  • 19. Stimulation of P-glycoprotein ATPase by analogues of tetramethylrosamine: coupling of drug binding at the "R" site to the ATP hydrolysis transition state.
    Tombline G; Donnelly DJ; Holt JJ; You Y; Ye M; Gannon MK; Nygren CL; Detty MR
    Biochemistry; 2006 Jul; 45(26):8034-47. PubMed ID: 16800628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PDE5 inhibitors: An original access to novel potent arylated analogues of tadalafil.
    Beghyn T; Hounsou C; Deprez BP
    Bioorg Med Chem Lett; 2007 Feb; 17(3):789-92. PubMed ID: 17107795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.